Replimune’s RP-1 resubmission overcame skepticism after FDA advisers voted it “evaluable and clinically meaningful,” putting the therapy back on track after repeated setbacks. The panel’s decision reduces the likelihood that the program returns to a confirmatory-trial path after earlier rejections and highlights how the FDA scrutinized trial design and responder analyses when RP-1 was previously reviewed.